Jupiter Neurosciences Inc

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 5 full-time employees. The company went IPO on 2024-12-03. The firm is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer market with its Nugevia product line. The firm's pharmaceutical product pipeline is built around its proprietary platform product, JOTROL, an enhanced oral formulation of resveratrol. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Its segments include premium nutritional supplements, and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. The firm's Nugevia product line supplements space, supporting mental clarity, skin health, and mitochondrial function. The company is also focused on a Phase IIa clinical study in Parkinson's disease. The company also has rights in ALA-002.